Research Site
Berlin, Germany
NCT Number: NCT00709553
The purpose of the study is to to assess the effect of multiple oral doses of ZD4054 (Zibotentan) on the pharmacokinetics of a CYP450 3A Probe (midazolam) in healthy male subjects.
Looking for future studies?
Notify Me18 year–65 year
Male
Interventional
Phase 1
Berlin, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Dormicum®
ZD4054 10 mg od
Other names: Zibotentan
Time frame: Frequent sampling occasions during study
Time frame: During the whole treatment period
AstraZeneca
Industry
A Randomised, Open-label, Crossover, Phase I Study to Assess the Effect of Multiple Oral Doses of ZD4054 (Zibotentan) on the Pharmacokinetics of a CYP450 3A Probe (Midazolam) in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07724015
Healthy
Jaén, Spain
View Trial DetailsNCT07404254
Beverage Intake, Caffeine
San Francisco, California, United States
View Trial DetailsNCT07466667
Healthy
Ahmedabad, Gujarat, India
View Trial DetailsNCT07357818
Beverage Intake, Caffeine
San Francisco, California, United States
View Trial Details